Abbott (ABT) ended the recent trading session at $115.29, demonstrating a +2.74% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 1.04%. Meanwhile, the Dow lost 1.66%, and the Nasdaq, a tech-heavy index, lost 1.13%. Shares of the maker of infant formula, medical devices and drugs witnessed a gain of 4.46% over the previous month, beating the performance of the Medical sector with its gain of 0.7%, and the S&P 500's gain of 1.75%.Analysts and ...

Core Viewpoint - Danone has blocked a batch of infant formula intended for the Singaporean market at the request of the Singapore Food Agency (SFA) [1] Company Summary - Danone is a French food manufacturer that has taken precautionary measures regarding its infant formula products [1] Industry Summary - The action taken by Danone highlights the regulatory oversight in the food industry, particularly concerning infant nutrition products [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The lead plaintiff acts on behalf of other class members in directing the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for securities class action settlements since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [3] Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from underinvestment and required substantial capital expenditures [4] - It is claimed that there were significant manufacturing deficiencies in Perrigo's infant formula facility, leading to overstated financial results [4] - The misleading statements about Perrigo's business operations resulted in investor damages when the true details became public [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the upcoming lead plaintiff deadline on January 16, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must file with the court by January 16, 2026 [2]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [3]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [3]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including significant underinvestment in maintenance and the need for substantial capital expenditures [4]. - It is claimed that these misstatements led to overstated financial results, including earnings and cash flow, which misled investors about the company's operations and prospects [4].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's acquisition of the infant formula business from Nestlé was significantly underinvested in maintenance and operational improvements [2] - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2] - The complaint states that there were significant manufacturing deficiencies in the facility related to the infant formula business [2] - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were overstated [2] - The positive statements made by the defendants regarding the Company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has over 70 employees dedicated to serving clients and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Perrigo Company plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its infant formula business and its financial results during the specified class period [1]. Group 1: Allegations - The complaint alleges that the infant formula business acquired from Nestlé suffered from significant underinvestment in maintenance, operational improvements, and repairs [1]. - Perrigo needed to make substantial capital and operational expenditures beyond the company's stated cost estimates to remediate the infant formula business [1]. - There were significant manufacturing deficiencies in the facility for the company's infant formula business [1]. - As a result of the aforementioned issues, the company's financial results, including earnings and cash flow, were overstated [1]. - The defendants' positive statements about the company's business, operations, and prospects were materially misleading and lacked a reasonable basis [1]. Group 2: Class Action Details - The class period for the lawsuit is from February 27, 2023, to November 4, 2025 [1]. - Shareholders are encouraged to register for the class action by January 16, 2026, to potentially be appointed as lead plaintiff [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive status updates throughout the lifecycle of the case [2].

Company Performance - Abbott's stock closed at $128.47, reflecting a +2.4% change from the previous day's closing price, outperforming the S&P 500's loss of 0.16% [1] - Over the past month, Abbott's shares have decreased by 3.93%, underperforming the Medical sector's gain of 1.12% and the S&P 500's loss of 0.21% [1] Upcoming Financial Results - Abbott's upcoming EPS is projected at $1.5, indicating an 11.94% increase compared to the same quarter of the previous year [2] - Revenue is expected to reach $11.79 billion, representing a 7.48% growth compared to the corresponding quarter of the prior year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $5.15 per share and revenue at $44.6 billion, reflecting changes of +10.28% and +6.33% respectively from the prior year [3] Analyst Estimates - Recent adjustments to analyst estimates for Abbott are important as they indicate changing near-term business trends, with upward revisions suggesting analysts' positivity towards the company's operations [4] - The consensus EPS projection has remained stable over the past 30 days, and Abbott currently holds a Zacks Rank of 3 (Hold) [6] Valuation Metrics - Abbott's Forward P/E ratio is 24.37, which is a premium compared to the industry average Forward P/E of 19.3 [6] - The company has a PEG ratio of 2.29, while the average PEG ratio for Medical - Products stocks is 1.92 [7] Industry Context - The Medical - Products industry, part of the Medical sector, has a Zacks Industry Rank of 165, placing it in the bottom 34% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Perrigo securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [2]. - The deadline to move the Court to serve as lead plaintiff is January 16, 2026, with the lead plaintiff representing other class members in the litigation [2]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [3]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from significant underinvestment and required substantial capital expenditures [4]. - It is claimed that there were significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [4]. - The lawsuit asserts that the positive statements made by Perrigo about its business operations were materially misleading and lacked a reasonable basis, resulting in investor damages when the true details emerged [4].

Core Viewpoint - A class action securities lawsuit has been filed against Perrigo Company plc, alleging securities fraud that affected investors between February 27, 2023, and November 4, 2025 [1] Group 1: Allegations of Fraud - The lawsuit claims that Perrigo's infant formula business, acquired from Nestlé, suffered from significant underinvestment in maintenance and operational improvements [2] - It is alleged that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2] - The complaint indicates that there were significant manufacturing deficiencies in the facility for the infant formula business [2] - As a result of these issues, Perrigo's financial results, including earnings and cash flow, were overstated [2] - The positive statements made by the defendants regarding the Company's business and prospects were materially misleading and lacked a reasonable basis [2] Group 2: Legal Process and Participation - Investors who suffered losses during the relevant time frame have until January 16, 2026, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, and participation does not require serving as a lead plaintiff [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4] - The firm has over 70 employees and has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - Rosen Law Firm is encouraging investors of Perrigo Company plc to secure legal counsel before the January 16, 2026 deadline for a securities class action lawsuit related to the company's performance during the specified class period [2][3]. Group 1: Class Action Details - The class period for the securities class action is from February 27, 2023, to November 4, 2025, inclusive [2]. - Investors who purchased Perrigo securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by January 16, 2026 [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [5]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its success in securities class action settlements [5]. Group 3: Case Allegations - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business, including issues related to underinvestment, necessary capital expenditures, and manufacturing deficiencies [6]. - As a result of these misstatements, Perrigo's financial results were overstated, leading to investor damages when the true information became public [6].